articleJournal of Neurology Neurosurgery & PsychiatryAug 21, 2003BRONZE OA

The prevalence and causes of dementia in people under the age of 65 years

RHRichard Harvey

Imperial College London · Geelong Hospital · +1 more institution

PubMed
Indexed incrossrefpubmed

Abstract

Combined neprilysin (NEP) inhibition (sacubitril) and angiotensin type 1 receptor (AT1R) antagonism (valsartan) is used in the treatment of congestive heart failure and is gaining interest for other angiotensin II (AngII)-related cardiovascular diseases. In addition to heart failure, AngII promotes hypertension, atherosclerosis, and abdominal aortic aneurysms (AAAs). Similarly, NEP substrates or products have broad effects on the cardiovascular system. In this study, we examined NEP inhibition (with sacubitril) and AT1R antagonism (with valsartan) alone or in combination on AngII-induced hypertension, atherosclerosis, or AAAs in male low-density lipoprotein receptor–deficient mice. Preliminary studies assessed…

Citation impact

638
total citations
FWCI
5.12
Percentile
100%
References
28
Citations per year

Authors

1

Topics & keywords

Topics
Keywords
  • Sacubitril
  • Valsartan
  • Sacubitril, Valsartan
  • Angiotensin II
  • Medicine
  • Blood pressure
  • Internal medicine
  • Renin–angiotensin system
UN Sustainable Development Goals
  • Reduced inequalities
No related works found for this paper.

Funding